Search results
A global initiative to deliver precision health in diabetes - Nature Medicine
Nature· 5 days agoP.W.F. was an employee of the Novo Nordisk Foundation at the time this Comment was written; the views expressed in this paper do not necessarily represent those of the Novo Nordisk Foundation ...
These 3 big-name FTSE 100 shares are stinking out my portfolio. Time to sell?
Fool.co.uk via Yahoo Finance UK· 5 days agoHarvey Jones is reviewing three FTSE 100 shares trailing the rest of his portfolio and asks, do they...
Sales from licensed and acquired products to increase by 2013 - Nature Reviews Drug Discovery
Nature· 4 days agoAbbott posts the largest relative drop (nearly 50%) as sales from organic products such as lopinavir/ritonavir (Kaletra) decrease and are replaced by revenue from licensed products such as adalimumab ...
FTSE 100 movers: Smurfit Westrock up on JPM note; water firms give back gains
ShareCast· 4 days agoLondon’s FTSE 100 was up 0.3% at 8,250.61 in afternoon trade on Friday.
These 3 big-name FTSE 100 shares are stinking out my portfolio. Time to sell?
Motley Fool UK· 5 days agoThree have fallen further since I added them to my portfolio. The big attraction is that JD has...
FDA balks on MedImmune's cell-grown flu vaccine - Nature Biotechnology
Nature· 4 days agoThe AstraZeneca subsidiary took this step after the US Food and Drug Administration (FDA) requested follow-on studies that would substantially increase the cost and time to ...
London open: FTSE gains as attention turns to US bank earnings
ShareCast· 4 days agoLondon stocks rose in early trade on Friday as investors turned their attention to the US, where...
Acute Migraine Treatment Market is growing at an 8.7% CAGR and is expected to reach USD 8.6 Billion
PharmiWeb· 1 day agoThe global Acute Migraine Treatment Market is on the rise, driven by the increasing prevalence of migraine headaches. According to recent projections, the market is set to reach a value of USD ...
Patent watch - Nature Reviews Drug Discovery
Nature· 4 days agoThe disputed patent (IN 196774) for Tarceva — an epidermal growth factor receptor type 1 (EGFR1) inhibitor that is used for the treatment of non-small-cell lung cancer — is owned jointly by ...
London midday: Stocks up on US rate cut hopes
ShareCast· 4 days agoLondon stocks were still in the black by midday on Friday, with sentiment boosted by US rate cut hopes, as investors turned their attention to bank...
